Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist

Journal of Investigative Dermatology

Volumn 134, Issue 7, 2014, Pages 1884-1892

  Fujiwara, Susumu ^a   Nagai, Hiroshi ^a   Shimoura, Noriko ^a   Oniki, Shuntaro ^a   Yoshimoto, Takayuki ^b   Nishigori, Chikako ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CD4 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 23; OX40 AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; IMMUNOGENICITY; MELANOMA; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MELANOMA; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; RATS; SKIN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84902533440     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.42     Document Type: Article

References (42)

1. Croft M (2010) Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28: 57-78
2. Dolcetti L, Peranzoni E, Ugel S et al. (2010) Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 40: 22-35
3. Dudley ME, Wunderlich JR, Yang JC et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-57
4. Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nat New Biol 242: 148-9
5. Fridlender ZG, Kapoor V, Buchlis G et al. (2011) Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 44: 230-7
6. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12: 253-68
7. Gehad AE, Lichtman MK, Schmults CD et al. (2012) Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. J Invest Dermatol 132: 2642-51
8. Giovarelli M, Cappello P, Forni G et al. (2000) Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol 164: 3200-6
9. Gough MJ, Ruby CE, Redmond WL et al. (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 68: 5206-15
10. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T et al. (2009) OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 206: 1103-16
11. Ishii N, Takahashi T, Soroosh P et al. (2010) OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol 105: 63-98
12. Jensen SM, Maston LD, Gough MJ et al. (2010) Signaling through OX40 enhances antitumor immunity. Semin Oncol 37: 524-32
13. Kjaergaard J, Tanaka J, Kim JA et al. (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60: 5514-21
14. Kodumudi KN, Weber A, Sarnaik AA et al. (2012) Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189: 5147-54
15. Kryczek I, Wei S, Zou L et al. (2007) Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-3
16. Langowski JL, Zhang X, Wu L et al. (2006) IL-23 promotes tumour incidence and growth. Nature 442: 461-5
17. Lesokhin AM, Hohl TM, Kitano S et al. (2012) Monocytic CCR2(+) myeloidderived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 72: 876-86
18. Lindau D, Gielen P, Kroesen M et al. (2013) The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138: 105-15
19. Lu T, Gabrilovich DI (2012) Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res 18: 4877-82
20. López M, Aguilera R, Pérez C et al. (2006) The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines. Immunobiology 211: 127-36
21. Meyer C, Sevko A, Ramacher M et al. (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108: 17111-6
22. Nagai H, Hara I, Horikawa T et al. (2000a) Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest 18: 206-13
23. Nagai H, Hara I, Horikawa T et al. (2000b) Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J Invest Dermatol 115: 1059-64
24. Nagaraj S, Youn JI, Weber H et al. (2010) Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 16: 1812-23
25. Oniki S, Nagai H, Horikawa T et al. (2006) Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 66: 6395-404
26. Pardee AD, McCurry D, Alber S et al. (2010) A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res 70: 9041-52
27. Peranzoni E, Zilio S, Marigo I et al. (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22: 238-44
28. Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205: 825-39
29. Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101(Suppl 2): 14639-45
30. Ruby CE, Yates MA, Hirschhorn-Cymerman D et al. (2009) Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol 183: 4853-7
31. Seo N, Hayakawa S, Takigawa M et al. (2001) Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103: 449-57
32. Sevko A, Sade-Feldman M, Kanterman J et al. (2012) Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol 133: 1610-9
33. Srivastava MK, Zhu L, Harris-White M et al. (2012) Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE 7:e40677
34. Sugamura K, Ishii N, Weinberg AD (2004) Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4: 420-31
35. Szatmári T, Lumniczky K, Désaknai S et al. (2006) Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 97: 546-53
36. Taraban VY, Rowley TF, O'Brien L et al. (2002) Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol 32: 3617-27
37. Weinberg AD, Morris NP, Kovacsovics-Bankowski M et al. (2011) Science gone translational: the OX40 agonist story. Immunol Rev 244: 218-218
38. Weinberg AD, Rivera MM, Prell R et al. (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164: 2160-9
39. Xiao X, Gong W, Demirci G et al. (2012) New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol 188: 892-892
40. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40: 2969-75
41. Zhao X, Rong L, Li X et al. (2012) TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 122: 4094-104
42. Zhu X, Fujita M, Snyder LA et al. (2011) Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 104: 83-92